ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC

MONDAY, June 4, 2018 -- For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news